Analysts can’t decide whether the “American Patients First” program will serve U.S. consumers well in the long run, but most agreed that the administration is right in attempting to tackle the complex and important issue of drug prices.
New research, conducted in Q4 2017 by TayganPoint Consulting Group and PharmaVoice, reveals that more than one in four life sciences companies expect large-scale transformation in the next three years.
Is it time for pharmacovigilance teams to utilize AI applications to improve adverse event reporting?
As you consider more efficient approaches for monitoring, searching, and distributing results to the pharmacovigilance team, here’s one information manager’s advice.
The FDA’s 2019 budget request is $5.8 billion. Here’s a look at what Commissioner Scott Gottlieb plans to do with the funds.
Commercial teams can no longer afford to be operating separately from R&D – silos between the two operations will start to break down.
Drug repurposing could help find cures for rare diseases faster, but trawling through research is a time-consuming and resource-heavy task.